In March 2021, AVEO announced it will regain rights to AV-203 outside of North America, its clinical-stage potent humanized IgG1 monoclonal antibody that targets ErbB3 (also known as HER3), following ...

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today highlighted its recent progress and outlined its 2021 outlook. “We remain keenly focused on building out our commercial team ahead of the ...

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial ...

BOSTON--(BUSINESS WIRE)-- AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Jefferies 2021 Virtual Healthcare ...

BOSTON, March 14, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the fourth quarter and ...

How Aveo finally won FDA approval for its drug, tivozanib, could be viewed as a story of persistence. It also reflects the changes in cancer therapies and how at least one company is finding a new ...

AVEO Pharmaceuticals (AVEO) shares ended the last trading session 89.1% higher at $15.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Aveo Oncology announced on Wednesday that the Food and Drug Administration approved its kidney cancer drug Fotivda, which it plans to make available in the US by the end of March. The news cheered ...

Aveo shares rose 17% Thursday morning, pointing to a second day of strong gains. The stock climbed 89% in the previous session after the FDA approval its renal cancer treatment. Aveo plans to make its ...

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer. In this ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The Boston-based company announced Wednesday that the drug ...